Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
life sciences
national blog main
boston top stories
clinical trials
deals
fda
san francisco blog main
akouos
astellas pharmaceuticals
azacitidine
beta-thalassemia
biotech ipos
california institute for biomedical research
dacogen
decibel therapeutics
decitabine
dna
dyne therapeutics
epigenetics
epizyme
farydak
flagship pioneering
frequency therapeutics
fulcrum therapeutics
harvard university
hearing loss
insulated genomic domains
investing
jeffrey karp
kaleido biosciences
mahesh karande
metacrine
multiple sclerosis
myotonic dystrophy type 1
national top stories
new york blog main
new york top stories
What
developing
3
×
medicines
3
×
therapeutics
drug
ipo
affects
aims
americans
approach
approved
based
biotech
brings
called
company
date
debuts
disorders
drugs
dyne
dyne’s
epigenetic
epigenetics
fda
field
flagship’s
frequency
genetic
hearing
loss
meds
million
millions
morning
muscle
muscular
new
omega
plans
preclinical
Language
unset
Current search:
boston
×
developing
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds